Stockscreener 앱 받기
113.56
0.88%
0.64
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week HighShould You Buy? - MarketBeat
FY2024 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 13.1% in January - MarketBeat
(AXSM) Proactive Strategies - Stock Traders Daily
H.C. Wainwright lifts Axsome stock target to $190 on FDA nod - MSN
Axsome Therapeutics' SWOT analysis: CNS drug developer's stock poised for growth - MSN
Axsome Therapeutics: Strategic Launch and Study Upside Drive Buy Rating - TipRanks
RBC Capital lifts Axsome stock target to $143, sees launch potential - MSN
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Truist Securities Adjusts Axsome Therapeutics Price Target to $190 From $180, Maintains Buy Rating - Marketscreener.com
Mizuho Raises Price Target on Axsome Therapeutics to $137 From $122, Keeps Outperform Rating - Marketscreener.com
RBC Lifts Price Target on Axsome Therapeutics to $143 From $139, Keeps Outperform Rating - Marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week HighShould You Buy? - MarketBeat
Moody Aldrich Partners LLC Sells 15,506 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why - MSN
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 at HC Wainwright - MarketBeat
Axsome gets FDA approval for Symbravo for migraine - MSN
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises - MSN
Musculoskeletal Pain Pipeline 2024: Therapies, MOA Insights, - openPR
FDA approves Axsome's novel migraine treatment SYMBRAVO By Investing.com - Investing.com Canada
Axsome’s Migraine Medicine Clears FDA Bar - BioSpace
Redemption complete for Axsome’s Symbravo in migraine - The Pharma Letter
Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs - MSN
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewswire
FDA Victory: Axsome's Revolutionary Migraine Drug SYMBRAVO Gets Green LightTop Expert Reveals Clinical Impact - StockTitan
FDA approves new migraine treatment SYMBRAVO By Investing.com - Investing.com Canada
FDA approves new migraine treatment SYMBRAVO - MSN
Axsome Shares Up Post Market After Hitting Record High on FDA Approval - MarketWatch
US FDA approves Axsome Therapeutics' migraine drug - Reuters
Big Moves in Tech: Buying Apple, Selling Dell - The Globe and Mail
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - The Manila Times
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® - GlobeNewswire
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the - The Bakersfield Californian
TD Cowen lifts Axsome stock target to $155, maintains Buy rating - MSN
Excessive Daytime Sleepiness Pipeline 2024: Key Companies, - openPR
Is Trump Media & Technology Group Stock a Buy? - The Globe and Mail
Axsome Therapeutics stock hits 52-week high at $105.18 By Investing.com - Investing.com South Africa
Axsome Therapeutics stock hits 52-week high at $105.18 - MSN
Axsome Shares Rise 19% in a Month: What's Driving the Rally? - MSN
3 Stocks Down 70% or More That Could Climb Back to $100 Per Share in 2025 - The Globe and Mail
Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month HighWhat's Next? - MarketBeat
William Blair Reiterates "Outperform" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
1.57%
1.13%
자본화:
|
볼륨(24시간):